Masonic Cancer Center, University of Minnesota: Leukemia, Prolymphocytic trials
The registry lists 12 Leukemia, Prolymphocytic studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 2 are open to participants now and 4 have results posted.
Phase 1 3Phase 2 7No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersRecruitingNCT03314974Phase 2
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
- Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic DiseasesTerminatedNCT02145039Not applicableResults posted
- Myeloablative Umbilical Cord Blood Transplantation in Hematological DiseasesCompletedNCT00309842Phase 2Results posted
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Treg Cells for AGVHD in Non-myeloablative UCB TransplantWithdrawnNCT02118311Phase 2
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or LymphomaCompletedNCT00889408Phase 1
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1